Abstract
There is increasing evidence that acute bacterial and viral infection represent trigger factors that temporarily elevate the risk of ischemic stroke. During and after influenza epidemics vascular death rates and hospitalizations for stroke are increased. Influenza vaccination is an effective measure to reduce hospitalization and mortality in the elderly and work incapacity in adults of working age. Results of several observational studies support the hypothesis that influenza vaccination is associated with reduced odds of stroke. As randomized studies are lacking, a causal role of influenza vaccination in stroke prevention is not proven, however. According to current guidelines in many countries, that recommend the vaccination in all patients with chronic vascular disease, all patients with a history of stroke or TIA should receive an influenza vaccination annually. Furthermore, patients with diabetes mellitus or with a combination of risk factors that increase stroke risk should obtain the vaccination. In addition, there is evidence from observational data that the neuraminidase inhibitor oseltamivir reduces the risk of stroke within 6 months after influenza infection.
Keywords: Acute infections, influenza, stroke, risk factor, cerebral ischemia, vascular disease, vaccination, antivirals
Infectious Disorders - Drug Targets
Title: Influenza and Stroke Risk: A Key Target Not to be Missed?
Volume: 10 Issue: 2
Author(s): Christian Urbanek, Frederick Palm and Armin J. Grau
Affiliation:
Keywords: Acute infections, influenza, stroke, risk factor, cerebral ischemia, vascular disease, vaccination, antivirals
Abstract: There is increasing evidence that acute bacterial and viral infection represent trigger factors that temporarily elevate the risk of ischemic stroke. During and after influenza epidemics vascular death rates and hospitalizations for stroke are increased. Influenza vaccination is an effective measure to reduce hospitalization and mortality in the elderly and work incapacity in adults of working age. Results of several observational studies support the hypothesis that influenza vaccination is associated with reduced odds of stroke. As randomized studies are lacking, a causal role of influenza vaccination in stroke prevention is not proven, however. According to current guidelines in many countries, that recommend the vaccination in all patients with chronic vascular disease, all patients with a history of stroke or TIA should receive an influenza vaccination annually. Furthermore, patients with diabetes mellitus or with a combination of risk factors that increase stroke risk should obtain the vaccination. In addition, there is evidence from observational data that the neuraminidase inhibitor oseltamivir reduces the risk of stroke within 6 months after influenza infection.
Export Options
About this article
Cite this article as:
Urbanek Christian, Palm Frederick and Grau J. Armin, Influenza and Stroke Risk: A Key Target Not to be Missed?, Infectious Disorders - Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/187152610790963474
DOI https://dx.doi.org/10.2174/187152610790963474 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Oral Anticoagulants in Peripheral Arterial and Coronary Artery Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review
Current Cardiology Reviews Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Nitric Oxide and Major Depressive Disorder: Pathophysiology and Treatment Implications
Current Molecular Medicine Vascular Protective Effects of Diabetes Medications that Mimic or Increase Glucagon-Like Peptide-1 Activity
Recent Patents on Cardiovascular Drug Discovery Fibrinolytic Factors in Liver Fibrosis
Current Pharmaceutical Biotechnology Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets The Role and Predictive Value of Cytokines in Atherosclerosis and Coronary Artery Disease
Current Medicinal Chemistry Diabetes Mellitus: An Update
Current Cardiology Reviews Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Milk Fat Globule Epidermal Growth Factor VIII Signaling in Arterial Wall Remodeling
Current Vascular Pharmacology Ethical and Social Issues in Pharmacogenomics Testing
Current Pharmaceutical Design Smoking and Hypertension: Effects on Clinical, Biochemical and Pathological Variables Due to Isolated or Combined Action on Cardiovascular System
Current Pharmaceutical Design Renin-Angiotensin System in Diabetes
Protein & Peptide Letters Unsafe Abortion: The Silent Endemic; An Avoidable Cause of Maternal Mortality. A Review
Current Women`s Health Reviews Traditional Cardiovascular Risk Factors in Adolescents with Type 1 Diabetes Mellitus
Current Diabetes Reviews HDL as a Target for Glycemic Control
Current Drug Targets EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors: Pitchai Balakumar and Gowraganahalli Jagadeesh)]
Current Molecular Pharmacology Actionable Nutrigenetics for Genetically Based Diseases? A New Critical Path to P4 Medicine
Current Pharmacogenomics and Personalized Medicine